Transcriptome profiling in neurodegenerative disease

Journal of Neuroscience Methods

Volumn 193, Issue 2, 2010, Pages 189-202

  Courtney, Eliza ^a   Kornfeld, Shan ^a   Janitz, Karolina ^a   Janitz, Michal ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alzheimer's disease; DNA microarrays; Huntington's disease; Next generation DNA sequencing; Parkinson's disease; RNA Seq; Transcriptome

Indexed keywords

TRANSCRIPTOME;

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; DEGENERATIVE DISEASE; DNA SPLICING; FOREBRAIN; FRONTAL CORTEX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MICROARRAY ANALYSIS; NEOCORTEX; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENILE PLAQUE; TEMPORAL CORTEX; TRANSCRIPTOMICS;

GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEURODEGENERATIVE DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 78049385467     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.08.018     Document Type: Review

References (160)

1. Altar C.A., Marshall J.F. Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors. Ann N Y Acad Sci 1988, 515:343-354.
2. Altar C.A., Jurata L.W., Charles V., Lemire A., Liu P., Bukhman Y., et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 2005, 58:85-96.
3. Altar C.A., Vawter M.P., Ginsberg S.D. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009, 34(1):18-54.
4. Altar C.A., Whitehead R.E., Chen R., Wortwein G., Masden T.M. Effects of electroconvulsive seizures and antidepressent drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003, 54:703-709.
5. Andorfer C., Acker C.M., Kress Y., Hof P.R., Duff K., Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005, 25:5446-5545.
6. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988, 50:1914-1923.
7. Bader Lange M.L., Cenini G., Piroddi M., Abdul H.M., Sultana R., Galli F., et al. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol Dis 2008, 29:456-464.
8. Bates G. Huntington's disease 2002, Oxford UP, Oxford. 3rd ed.
9. Blalock E.M., Chen K.C., Sharrow K., Herman J.P., Porter N.M., Foster T.C., et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 2003, 23:3807-3819.
10. Boissiere F., Faucheux B., Ruberg M., Agid Y., Hirsch E.C. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp Neurol 1997, 145:245-252.
11. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
12. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002, 29:23-39.
13. Callahan L.M., Coleman P.D. Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficitys in Alzheimer's disease. Neurobiol Aging 1995, 16:311-314.
14. Callahan L.M., Vaules W.A., Coleman P.D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 1999, 58:275-287.
15. Carter T.L., Rissman R.A., Mishizen-Eberz A.J., Wolfe B.B., Hamilton R.L., Gandy S., et al. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage. Exp Neurol 2004, 187:299-309.
16. Cheetham J.E., Coleman P.D., Chow N. Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. J Neurosci Methods 1997, 77:43-48.
17. Chin M.H., Qian W.J., Wang H., Petyuk V.A., Bloom J.S., Sforza D.M., et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res 2008, 4:4.
18. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004, 279:13256-13264.
19. Chow N., Cox C., Callahan L.M., Weimer J.M., Guo L., Coleman P.D. Expression profiles of multiple genes in single neurons of Alzheimer's disease. Proc Natl Acad Sci USA 1998, 95:9620-9625.
20. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006, 494:495-514.
21. Clark T.A., Sugnet C.W., Ares M. Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 2002, 296:907-910.
22. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signalling. J Neurosci Res 2002, 70:462-473.
23. Cole G., Dobkins K.R., Hansen L.A., Terry R.D., Saitoh T. Decreased levels of protein kinase C in Alzheimer brain. Brain Res 1988, 452:165-174.
24. Cortini F., Fenoglio C., Guidi I., Venturelli E., Pomati S., Marcone A., et al. Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur J Neurol 2008, 15:1111-1117.
25. Counts S.E., He B., Che S., Ikonomovic M.D., DeKosky S.T., Ginsberg S.D., et al. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 2007, 64:1771-1776.
26. Counts S.E., Nadeem M., Wuu J., Ginsberg S.D., Saragovi H.U., Mufson E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004, 56:520-531.
27. Counts S.E., Perez S.E., Ginsberg S.D., De Lacalle S., Mufson E.J. Galanin in Alzheimer disease. Mol Interv 2003, 3:137-156.
28. Cowburn R.F., Vestling M., Fowler C.J., Ravid R., Winblad B., O'Neill C. Disrupted 1-adrenoceptor-G protein coupling in the temporal cortex of patients with Alzheimer's disease. Neurosci Lett 1993, 155:163-166.
29. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging 1986, 7:3-7.
30. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
31. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990, 27:457-464.
32. Duke D.C., Moran L.B., Kalaitzakis M.E., Deprez M., Dexter D.T., Pearce R.K., et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 2006, 7:139-148.
33. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
34. Dunning M.J., Smith M.L., Ritchie M.E., Tavare S. Beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007, 23:2183-2184.
35. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res 2002, 136:267-275.
36. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989, 262:2551-2556.
37. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
38. Ginsberg S.D. Expression profile analysis of brain aging. Brain Aging: Models, Methods and Mechanisms 2007, CRC Press, New York. D.R. Riddle (Ed.).
39. Ginsberg S.D., Che S., Counts S.E., Mufson E.J. Shift in the ratio of 3-repeat tau and 4-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 2006, 96:1401-1408.
40. Ginsberg S.D., Che S., Counts S.E., Mufson E.J. Single cell gene expression profiling in Alzheimer's disease. NeuroRx 2006, 3:302-318.
41. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 2006, 97:475-487.
42. Ginsberg S.D., Crino P.B., Hemby S.E., Weingarten J.A., Lee V.M.-Y., Eberwine J.H., et al. Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 1999, 45:174-181.
43. Ginsberg S.D., Elarova I., Ruben M., Tan F., Counts S.E., Eberwine J.H., et al. Single cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem Res 2004, 29:1054-1065.
44. Ginsberg S.D., Hemby S.E., Lee V.M.-Y., Eberwine J.H., Trojanowski J.Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 2000, 48:77-87.
45. Ginsberg S.D., Schmidt M.L., Crino P.B., Eberwine J.H., Lee V.M.-Y., Trojanowski J.Q. Molecular pathology of Alzheimer's disease and related disorders. Cerebral Cortex. Neurodegenerative and Age-Related Changes in Structure and Function of Cerebral Cortex 1999, vol. 14. Kluwer Academic/Plenum, New York.
46. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
47. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989, 8:393-399.
48. Gotz J. Tau and transgenic animal models. Brain Res Brain Res Rev 2001, 35:266-286.
49. Greene J.G., Dingledine R., Greenamyre J.T. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in Parkinsonism. Neurobiol Dis 2005, 18:19-31.
50. Grunblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004, 111:1543-1573.
51. Grunblatt E., Mandel S., Maor G., Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 2001, 78:1-12.
52. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000, 74:237-243.
53. Gutala R.V., Reddy P.H. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. J Neurosci Methods 2004, 132:101-107.
54. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. PNAS 2001, 98:4746-4751.
55. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
56. Hata R., Masumura M., Akatsu H., Li F., Fujita H., Nagai Y., et al. Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun 2001, 284:310-316.
57. Hauser M.A., Li Y.J., Xu H., Noureddine M.A., Shao Y.S., Gullans S.R., et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia in parkinsonism. Arch Neurol 2005, 62:917-921.
58. Ho G.J., Drego R., Hakimian E., Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005, 4:247-256.
59. Ho L., Guo Y., Spielman L., Petrescu O., Haroutunian V., Purohit D., et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 2001, 298:91-194.
60. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15:965-977.
61. Hyman B.T., Van Hoesen G.W., Damasio A.R., Barnes C.L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
62. Hyman B.T., Van Hoesen G.W., Kromer L.J., Damasio A.R. Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 1986, 20:472-481.
63. Ikonomovic M.D., Sheffield R., Armstrong D.M. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus 1995, 5:469-486.
64. International Human Genome Sequencing Consortium. " Finishing the euchromatic sequence of the human genome." Nature 2004;431:931-45.
65. Iqbal K., del C., Alonso A., Chen S., Chohan M.O., El-Akkad E., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
66. Iwata S., Nomoto M., Miyata A. A microarray analysis of laser capture microdissected substantia nigra pars compacta after a single administration of MPTP in common marmosets. Nihon Shinkei Seishin Yakurigaku Zasshi 2007, 27:161-166.
67. Jacob C.P., Koutsilieri E., Bartl J., Neuen-Jacob E., Arzberger T., Zander N., et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 2007, 11:97-116.
68. Janitz M, editor. Next-generation genome sequencing - towards personalized medicine. Weinheim: Wiley-VCH; 2008.
69. Johnston N.L., Cervenak J., Shore A.D., Torrey E.F., Yolken R.H. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J. Neurosci Methods 1997, 77:83-92.
70. Joyce J.N., Kaeger C., Ryoo H., Goldsmith S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neurosci Lett 1993, 154:171-174.
71. Jurata L.W., Bukhman Y.V., Charles V., Capriglione F., Bullard J., Lemire A.L., et al. Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. J Neurosci Methods 2004, 138:173-188.
72. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10:381-391.
73. Kapur K., Xing Y., Ouyang Z., Wong W.H. Exon arrays provide accurate assessments of gene expression. Genome Biol 2007, 8:R82.
74. Konig R., Baldessari D., Pollet N., Niehrs C., Eils R. Reliability of gene expression ratios for cDNA microarrays in multiconditional experiments with a reference design. Nucleic Acids Res 2004, 32:e29.
75. Kumar U., Patel S.C. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 2007, 1131:187-196.
76. Lad S.P., Neet K.E., Mufson E.J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Target CNS Neurol Disord 2003, 2:315-334.
77. Lai M.K., Lai O.F., Keene J., Esiri M.M., Francis P.T., Hope T., et al. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 2001, 57:805-811.
78. Lai M.K., Tsang S.W., Alder J.T., Keene J., Hope T., Esiri M.M., et al. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology 2005, 179:673-677.
79. Li H., Ruan J., Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008, 18:1851-1858.
80. Li R., Li Y., Kristiansen K., Wang J. SOAP: short oligonucleotide alignment program. Bioinformatics 2008, 24:713-714.
81. Li Z., Su Z., Wen Z., Shi L., Chen T. Microarray platform consistency is revealed by biologically functional analysis of gene expression profiles. BMC Bioinformatics 2009, 10:S12.
82. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005, 22:1942-1950.
83. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
84. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
85. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996, 14:1675-1680.
86. Loring J.F., Wen X., Lee J.M., Seilhamer J., Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol 2001, 20:683-695.
87. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002, 11:1911-1926.
88. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000, 9:1259-1271.
89. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 2002, 11:1927-1937.
90. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005, 1053:356-375.
91. Mandel S., Weinreb O., Youdim M. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol Sci 2003, 24:184-191.
92. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kretz O., Martin Villalba A., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 2002, 31:47-54.
93. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998, 150:40-44.
94. Maruszak A., Safranow K., Gustaw K., Kijanowska-Haładyna B., Jakubowska K., Olszewska M., et al. PIN1 gene variants in Alzheimer's disease. BMC Med Genet 2009, 10:115.
95. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000, 9:2197-2202.
96. Merrick S.E., Trojanowski J.Q., Lee V.M.-Y. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J Neurosci 1997, 17:5726-5737.
97. MIAME. 2009. Viewed July 13 2010, http://www.mged.org/Workgroups/MIAME/miame.html.
98. Miller J.A., Oldham M.C., Geschwind D.H. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci 2008, 28:1410-1420.
99. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., et al. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-lesioned mouse substantia nigra. J Neurosci 2004, 24:7445-7454.
100. Miller R.M., Kiser G.L., Kaysser-Kranich T.M., Lockner R.J., Palaniappan C., Federoff H.J. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 2006, 21:305-313.
101. Mockler T.C., Ecker J.R. Application of DNA tiling arrays for whole-genome analysis. Genomics 2005, 85:1-15.
102. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008, 5:621-628.
103. Mufson E.J., Bothwell M., Kordower J.H. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 1989, 105:221-232.
104. Mufson E.J., Counts S.E., Che S., Ginsberg S.D. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Prog Brain Res 2006, 159:197-222.
105. Mufson E.J., Counts S.E., Ginsberg S.D. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res 2002, 27:1035-1048.
106. Mufson E.J., Ikonomovic M.D., Styren S.D., Counts S.E., Wuu J., Leurgans S., et al. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol 2003, 60:1143-1148.
107. Mullis K.B. The unusual origin of the polymerase chain reaction. Sci Am 1990, 262:56-65.
108. Nagalakshmi U., Wang Z., Waern K., Shou C., Raha D., Gerstein M., et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 2008, 320:1344-1349.
109. Napolitano M., Centonze D., Calce A., Picconi B., Spiezia S., Gulino A., et al. Experimental Parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis 2002, 10:387-395.
110. Newton S.S., Collier E.F., Hunsberger J., Adams D., Terwilliger R., Selvanayagam E., et al. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003, 15:7539-7547.
111. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressent drug treatments. J Neurosci 1995, 15:7539-7547.
112. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
113. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
114. Patel S., Singh K., Singh S., Singh M.P. Gene expression profiles of mouse striatum in control and maneb+paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol Biotechnol 2008, 40:59-68.
115. Phillips J., Eberwine J.H. Antisense RNA amplification: a linear amplification method for analyzing the mRNA population from single living cells. Methods Enzymol Suppl 1996, 10:283-288.
116. Plassman B.L., Langa K.M., Fisher G.G., Heeringa S.G., Weir D.R., Ofstedal M.B., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29:125-132.
117. Prabakaran S., Swatt J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 9:684-697.
118. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998, 21:479-505.
119. Ryoo H.L., Joyce J.N. Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer's disease. J Comp Neurol 1994, 348:94-110.
120. Sassin I., Schultz C., Thal D.R., Rub U., Arai K., Braak E., et al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol (Berl) 2000, 100:259-269.
121. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 2003, 24:1029-1046.
122. Schulze A., Downward J. Navigating gene expression using microarrays - a technology review. Nat Cell Biol 2001, 3:190-195.
123. Shepherd C., McCann H., Halliday G.M. Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol 2009, 118:37-52.
124. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
125. Shi L., Reid L.H., Jones W.D., Shippy R., Warrington J.A., Baker S.C., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24:1151-1161.
126. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 2000, 26:29-36.
127. Shobab L.A., Hsiung G.Y., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol 2005, 4:841-852.
128. Singleton A.B., Hall R., Ballard C.G., Perry R.H., Xuereb J.H., Rubinsztein D.C., et al. Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation. Brain 2000, 123:2467-2474.
129. Smith A.D., Xuan Z., Zhang M.Q. Using mapping quality scores and longer reads improves accuracy of Solexa read mapping. BMC Bioinformatics 2008, 9:128.
130. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001, 24:1217-1281.
131. Spillantini M.G., Schmidt M.L., Lee V.M.-Y., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
132. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Gen 2003, 19:233-237.
133. Sutherland G.T., Matigian N.A., Chalk A.M., Anderson M.J., Silburn P.A., Mackay-Sim A., et al. A cross-study transcriptional analysis of Parkinson's disease. PLoS ONE 2009, 4:e4955.
134. Sze C.I., Bi H., Kleinschmidt-DeMasters B.K., Filley C.M., Martin L.J. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 2000, 175:81-90.
135. Sze C.I., Troncoso J.C., Kawas C., Mouton P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997, 56:933-944.
136. Tanahashi H., Tabira T. Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production. Neurosci Lett 2001, 307:9-12.
137. Tang K., Wang C., Shen C., Sheng S., Ravid R., Jing N. Identification of a novel alternative splicing isoform of human amyloid precursor protein gene APP639. Eur J Neurosci 2003, 18:102-108.
138. Teng K.K., Hempstead B.L. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 2004, 61:35-48.
139. Trapnell C., Pachter L., Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25:1105-1111.
140. Trapnell C., Williams B.A., Pertea G., Mortazavi A., Kwan G., van Baren M.J., et al. Transcript assembly and quantification by RNA-Seq revels unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010, 28:511-515.
141. Trojanowski J.Q., Lee V.M.-Y. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998, 55:151-152.
142. Trojanowski J.Q., Lee V.M.-Y. The Alzheimer's brain: finding out what's broken tells us how to fix it. Am J Pathol 2005, 167:1183-1188.
143. Tsang S.W., Pomakian J., Marshall G.A., Vinters H.V., Cummings J.L., Chen C.P., et al. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging 2007, 28:1381-1387.
144. Vera J.C., Wheat C.W., Fescemyer H.W., Frilander M.J., Crawford D.L., Hanski I., et al. Rapid transcriptome characterization for a nonmodel organism using 454 pyrosequencing. Mol Ecol 2008, 17:1636-1647.
145. Vogt I.R., Lees A.J., Evert B.O., Klockgether T., Bonin M., Wullner U. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Exp Neurol 2006, 199:465-478.
146. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44:559-577.
147. Walter J., Kaether C., Steiner H., Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001, 11:585-590.
148. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
149. Wang J.-Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008, 85:148-175.
150. Warpman U., Alafuzoff I., Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain - alterations in Alzheimer's disease. Neurosci Lett 1993, 150:39-43.
151. Westphalen R.I., Scott H.L., Dodd P.R. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease. J Neural Transm 2003, 110:1013-1027.
152. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10:122-126.
153. Wollmer M.A., Streffer J.R., Lutjohann D., Tsolaki M., Iakovidou V., Hegi T., et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 2003, 24:421-426.
154. Wu J.Y., Kar A., Kuo D., Yu B., Havlioglu N. SRp54 (SFRS11), a regulator for tau exon 10 alternative splicing identified by an expression cloning strategy. Mol Cell Biol 2006, 26:6739-6747.
155. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
156. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 2001, 10:1829-1845.
157. Yamada T., Goto I., Sakaki Y. Neuron-specific splicing of the Alzheimer amyloid precursor protein gene in a mini-gene system. Biochem Biophys Res Commun 1993, 195:442-448.
158. Yao P.J., Zhu M., Pyun E.I., Brooks A.I., Therianos S., Meyers V.E., et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 2003, 12:97-109.
159. Yasuda R.P., Ikonomovic M.D., Sheffield R., Rubin R.T., Wolfe B.B., Armstrong D.M. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res 1995, 678:161-167.
160. Zhu X., Lee H.G., Raina A.K., Perry G., Smith M.A. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 2002, 11:270-281.